知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

185 条记录 (耗时 0.024 秒)

    Method for making 3-deoxyanthocyanidins
    31.
    发明授权
    Method for making 3-deoxyanthocyanidins 失效
    制备3-脱氧山梨糖苷的方法

    公开(公告)号：US4105675A

    公开(公告)日：1978-08-08

    申请号：US662742

    申请日：1976-03-01

    申请人： Guillermo A. Iacobucci ,  James G. Sweeny

    发明人： Guillermo A. Iacobucci ,  James G. Sweeny

    IPC分类号： A23L1/275 ,  C07D311/32 ,  C07D311/60 ,  C07D311/64 ,  C09B61/00

    CPC分类号： C07D311/32 ,  C07D311/60 ,  C07D311/64

    摘要： Method for preparing a 3-deoxy-5-hydroxyanthocyanidin salt having a 4' and/or 7 OH substituent from a corresponding acylated flavanone, by (1) reducing the acylated flavanone in a solvent medium by reaction with an alkali borohydride to form a corresponding flavan not having an OH substituent at the 4 position, and (2) oxidizing the flavan or an acylated or hydrolyzed derivative of the flavan in an organic solvent medium by reaction with a halogenated benzoquinone in the presence of a strong acid and water. Suitable acylated flavanones include acetylated natural flavanones, especially acetylated naringenin and hesperetin.

    2,4,7-substituted 5-hydroxy benzopyrans and esters
    32.
    发明授权
    2,4,7-substituted 5-hydroxy benzopyrans and esters 失效
    2,4,7-取代的5-羟基苯并吡喃和酯

    公开(公告)号：US3947462A

    公开(公告)日：1976-03-30

    申请号：US472243

    申请日：1974-05-22

    申请人： David Lloyd Arendsen ,  Martin Winn

    发明人： David Lloyd Arendsen ,  Martin Winn

    IPC分类号： C07C37/055 ,  C07D311/60

    CPC分类号： C07C37/055 ,  Y10S514/96

    摘要： 2,4,7-Substituted 5-hydroxy benzopyrans and dihydrobenzopyrans and their esters represented by the formulae ##SPC1##Wherein each R.sub.1 is loweralkyl, and R.sub.2 is hydrogen, loweralkanoyl or ##SPC2##With Y being a straight or branched chain alkylene group having from 1-8 carbon atoms; a is an integer from 1-4; b is an integer from 1-4; X is CH.sub.2, O, S, or NR.sub.5 with R.sub.5 being hydrogen or loweralkyl, with the limitation that when X is O, S, or NR.sub.5, the sum of a and b is 3 or 4 and R.sub.4 is hydrogen or loweralkyl; and R.sub.3 is ##SPC3##With Y' being a straight or branched chain alkylene group having from 1-10 carbon atoms; and each R.sub.7, R.sub.8 and R.sub.9 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl and the pharmaceutically acceptable salts thereof.

    摘要翻译： 2,4,7-取代的5-羟基苯并吡喃和二氢苯并吡喃及其由下式表示的酯其中R 1为低级烷基，R 2为氢，低级烷酰基或Y Y为具有1-8个碳原子的直链或支链亚烷基 ; a是1-4的整数; b是1-4的整数; X为CH 2，O，S或NR 5，其中R 5为氢或低级烷基，限制在X为O，S或NR 5时，a和b之和为3或4，R4为氢或低级烷基; 并且R 3为Y Y'为具有1-10个碳原子的直链或支链亚烷基; 并且每个R 7，R 8和R 9是由氢，卤素，三氟甲基或低级烷基组成的组的相同或不同的成员及其药学上可接受的盐。

    THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS
    37.
    发明申请
    THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS 审中-公开

    公开(公告)号：US20200253918A1

    公开(公告)日：2020-08-13

    申请号：US16697894

    申请日：2019-11-27

    申请人： Henry Lowe ,  Ngeh J. Toyang

    发明人： Henry Lowe ,  Ngeh J. Toyang

    IPC分类号： A61K31/352 ,  C07D311/60 ,  C07D311/32 ,  A61K31/353 ,  A61P35/02

    摘要： A cannabis-based flavonoid pharmaceutical composition including any one or more selected from among the group of Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among the group of Geraldol, Rhamnetin, Isorhamnetin, Rhamnazin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and histone acetylases. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include but are not limited to brain, breast, colon, renal liver, lung, pancreatic, pigmented villonodular synovitis, prostate, leukemia, melanomam, tenosynovial giant cell tumor, as well as any other cancers that overexpress the oncogenic factors inhibited, by the cannabis flavonoids or their derivatives herein identified.